Financials · financial year 2025, full format
Annual accounts 2025 filed on 02-06-2026 PDF all 50 filings
Turnover
€358.3m▲ 6.5%
2024 · €336.5m
EBIT margin
4.2%▼ 6.5pp
2024 · 10.8%
Net result
€3.7m▼ 84.2%
2024 · €23.2m
Working capital
€141.2m▲ 11.9%
2024 · €126.1m
In the rankings
#4 employer in Elsene, Wholesale and retail trade sector#4 company by total assets in Elsene, Wholesale and retail trade sector#7 oldest company in Elsene, Wholesale and retail trade sector
Multi-year overview
2018 to 2025, 8 financial yearsTurnover
€358.3m
▲ 6.5%
2025
20182025
Operating result
€15.1m
▼ 58.2%
2025
20182025
Net result
€3.7m
▼ 84.2%
2025
highest quarter of the sector
20182025
EBIT margin
4.2%
▼ 6.5pp
2025
20182025
Equity
no figure
2025
20182025
Total assets
€377.4m
▼ 20.5%
2025
highest quarter of the sector
20182025
Debt
€226.6m
▼ 34.5%
2025
20182025
Working capital
€141.2m
▲ 11.9%
2025
highest quarter of the sector
20182025
Solvency
no figure
2025
20182025
Current ratio
1.63
▲ 0.26
2025
middle half of the sector
20182025
Return on assets (ROA)
1.0%
▼ 3.9pp
2025
middle half of the sector
20182025
Staff (FTE)
297
▼ 8.0%
2025
highest quarter of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€148.7m-€220.6m▲ 48.4%€240.2m▲ 8.9%€469.5m▲ 95.5%€548.2m▲ 16.8%€349.4m▼ 36.3%€336.5m▼ 3.7%€358.3m▲ 6.5%
Operating result€12.1m-€12.5m▲ 3.1%€14.7m▲ 18.3%€27.1m▲ 83.9%€29.8m▲ 10.1%€20.7m▼ 30.7%€36.2m▲ 75.2%€15.1m▼ 58.2%
Net result€8.0m-€9.4m▲ 16.7%€9.7mabove the sector's middle half▲ 2.9%€19.5mabove the sector's middle half▲ 102%€21.6mabove the sector's middle half▲ 10.7%€12.9mabove the sector's middle half▼ 40.3%€23.2mabove the sector's middle half▲ 79.7%€3.7mabove the sector's middle half▼ 84.2%
EBIT margin8.1%-5.6%▼ 2.5pp6.1%▲ 0.5pp5.8%▼ 0.4pp5.4%▼ 0.3pp5.9%▲ 0.5pp10.8%▲ 4.8pp4.2%▼ 6.5pp
Equity€89.8m-€139.7m▲ 55.6%€99.3mabove the sector's middle half▼ 28.9%€118.8mabove the sector's middle half▲ 19.7%€90.4mabove the sector's middle half▼ 23.9%
Total assets€166.9m-€283.8m▲ 70.0%€194.2mabove the sector's middle half▼ 31.6%€254.7mabove the sector's middle half▲ 31.2%€285.3mabove the sector's middle half▲ 12.0%€383.4mabove the sector's middle half▲ 34.4%€474.6mabove the sector's middle half▲ 23.8%€377.4mabove the sector's middle half▼ 20.5%
Debt€73.7m-€141.8m▲ 92.5%€92.3m▼ 34.9%€132.2m▲ 43.2%€183.5m▲ 38.8%€275.7m▲ 50.3%€346.0m▲ 25.5%€226.6m▼ 34.5%
Working capital€87.6m-€136.5m▲ 55.8%€94.0mabove the sector's middle half▼ 31.2%€114.5mabove the sector's middle half▲ 21.8%€91.4mabove the sector's middle half▼ 20.2%€123.1mabove the sector's middle half▲ 34.7%€126.1mabove the sector's middle half▲ 2.5%€141.2mabove the sector's middle half▲ 11.9%
Solvency53.8%-49.2%▼ 4.6pp51.2%within the sector's middle half▲ 1.9pp46.7%within the sector's middle half▼ 4.5pp31.7%within the sector's middle half▼ 15.0pp
Current ratio2.25-2.01▼ 0.242.05within the sector's middle half▲ 0.041.88within the sector's middle half▼ 0.171.50within the sector's middle half▼ 0.381.49within the sector's middle half▼ 0.011.37within the sector's middle half▼ 0.121.63within the sector's middle half▲ 0.26
Return on assets (ROA)4.8%-3.3%▼ 1.5pp5.0%within the sector's middle half▲ 1.7pp7.7%within the sector's middle half▲ 2.7pp7.6%within the sector's middle half▼ 0.1pp3.4%within the sector's middle half▼ 4.2pp4.9%within the sector's middle half▲ 1.5pp1.0%within the sector's middle half▼ 3.9pp
Staff (FTE)279.6-319.4▲ 14.2%330.1above the sector's middle half▲ 3.4%333.4above the sector's middle half▲ 1.0%336.3above the sector's middle half▲ 0.9%338.2above the sector's middle half▲ 0.6%323above the sector's middle half▼ 4.5%297above the sector's middle half▼ 8.0%
above
within
below
The sector band is the middle half of the companies in Wholesale trade (NACE 46). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 58% lower than in 2024 and the lowest since 2021.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €377.4m
Fixed assets
€11.4m ▲ 12.9%
Current assets
€365.9m ▼ 21.2%
Key figures and ratios
EBITDA
€16.2m▼
2024 · €37.3m
Cash flow
€4.7m▼
2024 · €24.2m
Quick ratio
0.85▲
2024 · 0.82
Interest coverage
5.67▼
2024 · 8.59
Debt ≤ 1 year
€224.7m▼
2024 · €338.4m
Income taxes
€9.1m▼
2024 · €9.5m
Customer credit
126 days▼
2024 · 175 days
Supplier credit
45 days▼
2024 · 125 days
Staff costs
€53.9m▼
2024 · €76.4m
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Securities and guarantees
| Item | 30-11-2021 | 30-11-2022 | 30-11-2023 | 30-11-2024 | 30-11-2025 |
|---|---|---|---|---|---|
| Guarantees given for others' debts | €108,900 | €108,900 | €108,900 | - | - |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
| Item | 30-11-2021 | 30-11-2022 | 30-11-2023 | 30-11-2024 | 30-11-2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €381,989 | €2.3m | €565,905 | €112,221 | €2.5m |
| Depreciation and write-downs of the year | €1.2m | €1.1m | €983,318 | €1.0m | €1.0m |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Auditor
| Item | 30-11-2021 | 30-11-2022 | 30-11-2023 | 30-11-2024 | 30-11-2025 |
|---|---|---|---|---|---|
| Fee for the audit | €54,000 | €56,000 | €63,800 | €64,697 | €71,697 |
Source: notes to the 2021 to 2025 annual accounts (relations with the auditor)
Subsidies and aid
European research
1 projectProgrammes
Projects
FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE
Public contracts
54 awards · 2024 to 2026
Antimycotica: Voriconazole IV
Antimycotica: Anidulafungine IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Azithromycine PO siroop
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Clindamycine PO
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Fluconazol PO caps
Show 45 more contracts
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Voriconazol IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Anidulafungine IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Azithromycine PO siroop
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Clindamycine PO
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Fluconazol PO caps
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Voriconazol IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Anidulafungine IV
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base de voriconazole (voie intraveineuse)
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base d'anidulafungine
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base de fluconazole (voie orale, comprimés)
Leveren van orale antibiotica: Azithromycine voor oraal gebruik
Leveren van orale antibiotica: Clindamycine voor oraal gebruik
Leveren van orale antibiotica: Linezolid voor oraal gebruik - tablet
Raamovereenkomst voor de levering van antimycotica: Anidulafungine IV
Raamovereenkomst voor de levering van antimycotica: Voriconazol PO siroop
Raamovereenkomst voor de levering van antimycotica: Voriconazol IV
Leveren van Trastuzumab en Rituximab voor intraveneus gebruik: Leveren van Trastuzumab 150 mg voor intraveneus gebruik
Bévacizumab
Diverse geneesmiddelen oncologie PO voor Helixziekenhuizen: Bosutinib
Diverse geneesmiddelen oncologie PO voor Helixziekenhuizen: Bosutinib
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: CLINDAMYCINE : Gélules
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: LINEZOLIDE : Solution
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: VORICONAZOL : Comprimés
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Linezolid - ATC J01XX08 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Anidulafungine - ATC J02AX06 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Linezolid - ATC J01XX08 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Anidulafungine - ATC J02AX06 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - IV
Raamovereenkomst voor het aankopen en leveren van Trastuzumab en Rituximab: Trastuzumab IV
Accord-cadre ayant pour objet la fourniture d'antibactériens par voie injectable: Tigécycline 50 mg, IV
Anti-infectieux à usage systémique: Tigécycline injectable
Anti-infectieux à usage systémique: Voriconazole injectable
Anti-infectieux à usage systémique: Anidulafungine injectable
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Linezolid inj
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Voriconazole inj
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Anidulafungin
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Azithromycine PO
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Clindamycine PO
The 50 most recent of 54 awards.
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | €222.9m | €282.6m | €317.3m | €543.0m | €632.9m | €413.6m | €392.6m | €414.1m | ▲ 5.5% |
| Turnover70 | €148.7m | €220.6m | €240.2m | €469.5m | €548.2m | €349.4m | €336.5m | €358.3m | ▲ 6.5% |
| Other operating income74 | €74.2m | €62.0m | €77.1m | €71.9m | €84.7m | €64.2m | €56.1m | €55.8m | ▼ 0.6% |
| Non-recurring operating income76A | - | - | - | €1.6m | - | - | - | - | - |
| Operating charges60/66A | €210.8m | €270.2m | €302.6m | €515.9m | €603.1m | €392.9m | €356.3m | €399.0m | ▲ 12.0% |
| Goods for resale, raw materials and consumables60 | €113.3m | €156.6m | €196.4m | €401.7m | €467.8m | €275.1m | €222.0m | €274.6m | ▲ 23.7% |
| Change in stocks: decrease (increase)609 | -€5.9m | -€21.5m | -€0.2m | €3.8m | -€40.0m | -€42.2m | -€23.7m | €17.3m | - |
| Services and other goods61 | €41.1m | €46.3m | €44.4m | €44.4m | €47.0m | €42.9m | €36.9m | €34.7m | ▼ 6.0% |
| Remuneration, social security and pensions62 | €41.1m | €48.5m | €50.9m | €56.5m | €66.1m | €64.9m | €76.4m | €53.9m | ▼ 29.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1.7m | €3.0m | €1.1m | €1.2m | €1.1m | €1.0m | €1.0m | €1.0m | ▼ 3.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | -€0.4m | €1.2m | €3.2m | -€1.8m | -€0.3m | €2.9m | €5.8m | -€4.4m | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | €2.2m | -€1.2m | €0.2m | €1.1m | €7.8m | -€7.0m | -€2.3m | €18.4m | - |
| Other operating charges640/8 | €11.9m | €15.8m | €6.3m | €12.8m | €13.5m | €13.2m | €16.5m | €20.8m | ▲ 26.1% |
| Operating profit (loss)9901 | €12.1m | €12.5m | €14.7m | €27.1m | €29.8m | €20.7m | €36.2m | €15.1m | ▼ 58.2% |
| Recurring financial income75 | €0.4m | €0.6m | €0.2m | €0.2m | €0.8m | €1.2m | €1.3m | €1.3m | ▼ 1.7% |
| Income from current assets751 | - | - | €0.01m | €0.01m | €0.1m | €0.7m | €1.1m | €0.7m | ▼ 31.0% |
| Other financial income752/9 | €0.4m | €0.6m | €0.2m | €0.2m | €0.7m | €0.4m | €0.3m | €0.6m | ▲ 124% |
| Financial charges65/66B | €0.5m | €0.8m | €0.3m | €0.3m | €1.0m | €3.8m | €4.9m | €3.7m | ▼ 25.4% |
| Recurring financial charges65 | €0.5m | €0.8m | €0.3m | €0.3m | €1.0m | €3.8m | €4.9m | €3.7m | ▼ 25.4% |
| Debt charges650 | - | - | €306 | €0.1m | €0.3m | €3.3m | €4.3m | €2.8m | ▼ 34.3% |
| Other financial charges652/9 | €0.5m | €0.8m | €0.3m | €0.2m | €0.7m | €0.5m | €0.6m | €0.8m | ▲ 43.5% |
| Profit (loss) for the period before taxes9903 | €11.9m | €12.3m | €14.6m | €27.0m | €29.6m | €18.0m | €32.6m | €12.8m | ▼ 60.8% |
| Income taxes67/77 | €3.9m | €3.0m | €5.0m | €7.5m | €8.0m | €5.1m | €9.5m | €9.1m | ▼ 3.5% |
| Taxes670/3 | €4.0m | €3.0m | €5.0m | €7.5m | €8.1m | €5.1m | €9.5m | €9.1m | ▼ 3.5% |
| Tax adjustments and reversals of tax provisions77 | €0.06m | - | €0.001m | €0.009m | €0.1m | - | - | - | - |
| Profit (loss) for the period9904 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| Profit (loss) for the period to be appropriated9905 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €166.9m | €283.8m | €194.2m | €254.7m | €285.3m | €383.4m | €474.6m | €377.4m | ▼ 20.5% |
| Fixed assets21/28 | €9.0m | €12.0m | €10.9m | €10.1m | €11.2m | €11.1m | €10.1m | €11.4m | ▲ 12.9% |
| Intangible fixed assets21 | €0.6m | - | - | - | - | - | - | - | - |
| Tangible fixed assets22/27 | €7.8m | €6.9m | €6.1m | €5.3m | €6.4m | €6.0m | €5.1m | €6.4m | ▲ 25.5% |
| Plant, machinery and equipment23 | €1.1m | €0.9m | €0.8m | €0.8m | €0.7m | €0.7m | €0.5m | €0.4m | ▼ 23.4% |
| Furniture and vehicles24 | €0.9m | €0.7m | €0.5m | €0.3m | €0.6m | €0.6m | €0.9m | €0.7m | ▼ 24.8% |
| Other tangible fixed assets26 | €5.8m | €5.2m | €4.7m | €4.1m | €4.3m | €4.1m | €3.5m | €3.0m | ▼ 15.6% |
| Assets under construction and advance payments27 | €0.006m | €0.2m | €0.1m | €0.08m | €0.8m | €0.6m | €0.09m | €2.3m | ▲ 26× |
| Financial fixed assets28 | €0.5m | €5.1m | €4.8m | €4.8m | €4.8m | €5.1m | €5.1m | €5.1m | ▲ 0.3% |
| Affiliated companies280/1 | €26 | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | = |
| Participating interests280 | €26 | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | = |
| Other financial fixed assets284/8 | €0.5m | €0.9m | €0.6m | €0.5m | €0.6m | €0.8m | €0.8m | €0.8m | ▲ 1.8% |
| Amounts receivable and cash guarantees285/8 | €0.5m | €0.9m | €0.6m | €0.5m | €0.6m | €0.8m | €0.8m | €0.8m | ▲ 1.8% |
| Current assets29/58 | €158.0m | €271.7m | €183.2m | €244.6m | €274.0m | €372.3m | €464.5m | €365.9m | ▼ 21.2% |
| Stocks and contracts in progress3 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Stocks30/36 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Goods purchased for resale34 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Amounts receivable within one year40/41 | €75.2m | €83.0m | €79.9m | €111.3m | €142.4m | €179.8m | €165.6m | €166.0m | ▲ 0.2% |
| Trade receivables40 | €73.1m | €80.9m | €74.2m | €109.6m | €136.3m | €171.0m | €161.0m | €123.7m | ▼ 23.2% |
| Other amounts receivable41 | €2.1m | €2.1m | €5.8m | €1.7m | €6.1m | €8.8m | €4.6m | €42.3m | ▲ 823% |
| Current investments50/53 | - | - | €381 | - | - | €0.06m | €87.1m | €0.02m | ▼ 100.0% |
| Other investments51/53 | - | - | €381 | - | - | €0.06m | €87.1m | €0.02m | ▼ 100.0% |
| Cash at bank and in hand54/58 | €21.2m | €90.5m | €8.8m | €40.7m | €0.7m | €21.9m | €21.3m | €23.9m | ▲ 12.1% |
| Deferred charges and accrued income490/1 | €1.5m | €2.9m | €2.0m | €2.2m | €0.2m | €0.4m | €2.5m | €0.9m | ▼ 63.8% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €166.9m | €283.8m | €194.2m | €254.7m | €285.3m | €383.4m | €474.6m | €377.4m | ▼ 20.5% |
| Equity10/15 | €89.8m | €139.7m | €99.3m | €118.8m | €90.4m | - | - | - | - |
| Contributions10/11 | €28.9m | €39.7m | €40.8m | €40.8m | €40.8m | €40.8m | €40.8m | €40.8m | = |
| Capital10 | €28.9m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | = |
| Issued capital100 | €28.9m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | = |
| Contributions outside capital11 | €0.8m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Share premium1100/10 | - | - | - | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Reserves13 | €5.9m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | = |
| Non-distributable reserves130/1 | - | - | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Legal reserve130 | €2.9m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Reserves not available under the articles1311 | €0.02m | €0.02m | - | - | - | - | - | - | - |
| Other1319 | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Tax-exempt reserves132 | €2.9m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Distributable reserves133 | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Profit (loss) carried forward14 | €54.2m | €90.8m | €50.5m | €70.0m | €41.6m | €54.5m | €77.7m | €81.4m | ▲ 4.7% |
| Provisions and deferred taxes16 | €3.5m | €2.3m | €2.5m | €3.6m | €11.4m | - | - | - | - |
| Provisions for liabilities and charges160/5 | €3.5m | €2.3m | €2.5m | €3.6m | €11.4m | €4.4m | €2.1m | €20.5m | ▲ 876% |
| Pensions and similar obligations160 | - | - | - | - | €3.7m | - | - | - | - |
| Other liabilities and charges164/5 | €3.5m | €2.3m | €2.5m | €3.6m | €7.6m | €4.4m | €2.1m | €20.5m | ▲ 876% |
| Amounts payable17/49 | €73.7m | €141.8m | €92.3m | €132.2m | €183.5m | €275.7m | €346.0m | €226.6m | ▼ 34.5% |
| Amounts payable within one year42/48 | €70.3m | €135.2m | €89.2m | €130.1m | €182.6m | €249.2m | €338.4m | €224.7m | ▼ 33.6% |
| Financial debts43 | - | - | - | - | €81.3m | €146.6m | €0.02m | €162.9m | ▲ 6,663× |
| Credit institutions430/8 | - | - | - | - | - | - | €0.02m | €0.8m | ▲ 34× |
| Other loans439 | - | - | - | - | €81.3m | €146.6m | - | €162.0m | - |
| Trade debts44 | €18.4m | €63.3m | €27.3m | €66.4m | €26.4m | €5.9m | €75.9m | €34.0m | ▼ 55.1% |
| Suppliers440/4 | €18.4m | €63.3m | €27.3m | €66.4m | €26.4m | €5.9m | €75.9m | €34.0m | ▼ 55.1% |
| Taxes, remuneration and social security45 | €52.0m | €71.9m | €61.9m | €63.7m | €75.0m | €76.4m | €255.6m | €23.3m | ▼ 90.9% |
| Taxes450/3 | €40.8m | €58.8m | €49.1m | €46.9m | €52.4m | €60.9m | €237.6m | €7.0m | ▼ 97.1% |
| Remuneration and social security454/9 | €11.2m | €13.2m | €12.8m | €16.8m | €22.5m | €15.6m | €18.0m | €16.3m | ▼ 9.3% |
| Other amounts payable47/48 | - | - | - | €0.02m | - | €20.3m | €6.9m | €4.5m | ▼ 35.0% |
| Accrued charges and deferred income492/3 | €3.4m | €6.6m | €3.1m | €2.1m | €0.8m | €26.5m | €7.7m | €1.9m | ▼ 74.7% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| + Depreciation and write-downs630 | €1.7m | €3.0m | €1.1m | €1.2m | €1.1m | €1.0m | €1.0m | €1.0m | ▼ 3.4% |
| Operating cash flow (approximation) | €9.7m | €12.3m | €10.8m | €20.7m | €22.7m | €13.9m | €24.2m | €4.7m | ▼ 80.7% |
| Investment in fixed assets (approximation) | - | -€6.0m | -€0.05m | -€0.3m | -€2.3m | -€0.8m | -€0.09m | -€2.3m | ▼ 2,470% |
| Change in cash | - | €69.3m | -€81.7m | €31.9m | -€40.0m | €21.2m | -€0.6m | €2.6m | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 50 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-11-2025 | full format | 02-06-2026 | 2026-00137670 | |
| 30-11-2024 | full format | 23-05-2025 | 2025-00110685 | |
| 30-11-2023 | full format | 21-05-2024 | 2024-00094385 | |
| 30-11-2022 | full format | 23-05-2023 | 2023-00098666 | |
| 30-11-2021 | full format | 01-06-2022 | 2022-20046669 | |
| 30-11-2020 | full format | 31-05-2021 | 2021-16800407 | |
| 30-11-2019 | full format | 29-06-2020 | 2020-22200444 | |
| 30-11-2018 | full format | 22-05-2019 | 2019-14500482 | |
| 30-11-2017 | full format | 30-05-2018 | 2018-15300114 | |
| 30-11-2016 | full format | 09-06-2017 | 2017-16800333 |